Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasHodgkin LymphomaIndolent LymphomasDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C81.-C82.-C82.7C82.9C83.1C83.3C84.4MeSHLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralSequenceChemotherapyChemo-substanceCarboplatinCytarabineDexamethasoneChemo-substanceCarboplatinCytarabineDexamethasoneChemo-substanceCarboplatinCytarabineDexamethasoneChemo-substanceCarboplatinCytarabineDexamethasoneNo. Substances3 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimNo. Substances5Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseInductionTherapy intentioncurativeRisksAnemia Hb below 8g/dlEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityNeuropathyNeutropeniaSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorTessoulin BDiseaseNon-Hodgkin-Lymphom / Hodgkin LymphomOriginNantes Medical University, Nantes, FranceProtocols in Revision 1 protocol foundProtocols under revision.DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)
